Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

$

-------------------------------------------------------------------------

Revenue:

Research contract 262,478 - 1,996,120

Product 60,675 21,392 280,049

Licensing fees 101,000 - 3,385,703

Research grant payments - - 273,663

-----------------------------------------------------------------------

424,153 21,392 5,935,535

Expenses:

Research and development,

net of tax credits 3,337,461 2,102,603 31,331,946

General and administrative 1,149,402 762,673 13,168,494

Foreign exchange loss (gain) (236,020) 319,481 508,201

Interest expense 551 771 906,768

-----------------------------------------------------------------------

4,251,394 3,185,528 45,915,409

-----------------------------------------------------------------------

Loss before the undernoted (3,827,241) (3,164,136) (39,979,874)

Interest income 69,720 181,484 2,221,804

Loss on extinguishment of debt - - (782,143)

-------------------------------------------------------------------------

Loss before income taxes (3,757,521) (2,982,652) (38,540,213)

Income taxes:

Current (59,416) (53,480) (394,438)

-------------------------------------------------------------------------

Loss and comprehensive loss

for the period (3,816,937) (3,036,132) (38,934,651)

Deficit, beginning of period (35,117,714) (23,783,289) -

---------------------------------
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... and TORONTO , March 5, ... a clinical-stage company developing new therapeutics and molecular diagnostics ... that William G. Rice , Ph.D., Chairman, President ... 27th Annual ROTH Conference on Tuesday, March 10 th ... Carlton, Laguna Niguel, CA. Dr. ...
(Date:3/5/2015)... Ohio (PRWEB) March 05, 2015 ... Gold Development Partner located in Northeast Ohio, today announced ... e2b teknologies to support its upgrade to the latest ... the largest independent group practice of its kind in ... and large volume of transactions, so efficiency and data ...
(Date:3/4/2015)... 2015 In an article published and posted ... Health Security review the clinical aspects of diseases caused ... bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related Conditions," ... of the New England Journal of Medicine . ... , and Tom Inglesby—review the clinical management of conditions ...
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report ... a characteristic that can be objectively measured and ... pathogenic processes as well as pharmacological responses to ...
Breaking Biology Technology:Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2Latest Clinical Information On Bioterrorism Threats 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3
... Annual Biotechnology Investor Conference, November 8, Features ... Small to Mid-cap Public Growth Companies Renowned Investment ... Stelios Papadopoulos, ... The Massachusetts Biotechnology,Council,s ninth annual MASS Opportunities Investor Conference, ...
... AACR press ... conference, ... biotechnology company discovering and developing the next wave of,antibody therapeutics, today ... an oral presentation on one of the six abstracts it,will present ...
... Varian Medical,Systems (NYSE: VAR ) ... market-leading,VariSeed(TM) brachytherapy seed planning software. VariSeed 8.0,incorporates ... of the,treatment. "The new features provide ... seeds in permanent seed implants," says Rebecca ...
Cached Biology Technology:2007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies 22007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies 3Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference 2Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference 3Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference 4Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 2Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 3
(Date:2/19/2015)... , Feb .19, 2015 Research and ... the addition of the "Military Electro-Optical / ... Sensor Technology, by Platform - Forecast to 2020" ... The military electro-optical/infrared systems market is expected to ... CAGR of 7.71%. This report segments ...
(Date:2/12/2015)... Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62/113114 for DISTRIBUTED METHOD AND SYSTEM ... The patent further establishes NXT-ID,s position in the emerging ... portfolio the ability for multiple devices to collaborate with ...
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... the portions of the heart damaged by a lack of ... avoid this scarring, which can harden the walls of the ... and eventually lead to heart failure. But new research from ... Medicine shows that interrupting this process can weaken heart function ...
... CAMDEN How the brain perceives color is one ... a stable perception of an object,s color as lighting conditions ... at RutgersCamden, has teamed up with psychologists from the University ... how this works. Allred conducted the research with ...
... This release is available in German . ... rails as far as they go. But nature also knows systems ... in a hamster wheel, a train caught up in such a ... Cluster of Excellence Nanosystems Initiative Munich have now succeeded in building ...
Cached Biology News:Scarring a necessary evil to prevent further damage after heart attack 2Rutgers-Camden researcher examines how the brain perceives shades of gray 2Rutgers-Camden researcher examines how the brain perceives shades of gray 3Perfect micro rings woven from muscle fibers 2Perfect micro rings woven from muscle fibers 3
Rabbit Anti-Ferret Whole Serum Antibody, Unconjugated...
... pAcGHLT-A,B,C Baculovirus ... Set,pAcGHLT-XylE Baculovirus ... Powder,Thrombin Dilution ... Cocktail,Insect Cell ...
... This product has been developed to ... peroxidase labeled proteins. Stability is increased ... to 2-8 centigrade. This product is ... no mercury or azide. This formulation ...
... been developed to significantly increase the shelf ... Stability is increased at room temperature storage ... This product is subjected to 0.2 micron ... This formulation insures consistently high levels ...
Biology Products: